Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial

Published:2022-05 Issue:5 Volume:23 Page:636-649
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Saji Shigehira,Taira Naruto,Kitada Masahiro,Takano Toshimi,Takada Masahiro,Ohtake Tohru,Toyama Tatsuya,Kikawa Yuichiro,Hasegawa Yoshie,Fujisawa Tomomi,Kashiwaba Masahiro,Ishida Takanori,Nakamura Rikiya,Yamamoto Yutaka,Toh Uhi,Iwata Hiroji,Masuda Norikazu,Morita Satoshi,Ohno Shinji,Toi Masakazu

Publisher

Elsevier BV

Subject

Oncology

Reference20 articles.

1. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology;Gradishar;J Natl Compr Canc Netw,2020

2. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02;Park;J Clin Oncol,2013

3. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer;Gennari;J Clin Oncol,2006

4. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial;Gligorov;Lancet Oncol,2014

5. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after firstline taxane and bevacizumab: a GINECO group study;Trédan;Ann Oncol,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105);Breast Cancer Research and Treatment;2024-07-05

2. Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities;Biomedicine & Pharmacotherapy;2024-06

3. A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105);2024-04-29

4. Construction of a mitochondria genes-based model for prognosis prediction, drug guidance and immune feature analysis in ovarian serous cystadenocarcinoma;2023-05-19

5. Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer;Biology;2023-05-09